Advocates & Other Big Data Stakeholders

Slides:



Advertisements
Similar presentations
Primary and secondary use of EHR: Enhancing clinical research Pharmaceutical Industry Perspectives Dr. Karin Heidenreich Senior Public Affairs Manager/Novartis.
Advertisements

Engaging Patients and Other Stakeholders in Clinical Research
National Coalition for Cancer Survivorship Meeting, Washington DC November 13, 2014 Steven Clauser, PhD, MPA Program Director, Improving Healthcare Systems.
So You Want to Do Comparative Effectiveness Research? The Nuts and Bolts of CER.
Truven Health Analytics State Exchanges - Data Collection & Analysis April 2014.
LIMITLESS POTENTIAL | LIMITLESS OPPORTUNITIES | LIMITLESS IMPACT Copyright University of Reading IMPACT AND THE SCIENCES Anthony Atkin (Research Impact.
DR EBTISSAM AL-MADI Consumer Informatics, nursing informatics, public health informatics.
RESEARCH DESIGN.
Internal Auditing and Outsourcing
Navigating Privacy and Security Issues for HIE: A Consumer Perspective Deven McGraw Chief Operating Officer National Partnership for Women & Families
Armenia and Diaspora Armenia’s investment climate and Diaspora’s participation in development policies. Hayk Sargsyan, Johns Hopkins University.
Group Technical Assistance Webinar August 5, CFPHE RESEARCH METHODS FOR COMPARATIVE EFFECTIVENESS RESEARCH.
Crosswalk of Public Health Accreditation and the Public Health Code of Ethics Highlighted items relate to the Water Supply case studied discussed in the.
Policy track summary ICIUM 2011 – 18 Nov Policy track topics 1.The pharmaceutical policy process 2.Quality and safety of medicines in LMIC 3.Policy.
PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE PCORI Board of Governors Meeting Washington, DC September 24, 2012 Anne Beal, MD, MPH, Chief Operating Officer.
Big Data for Breast Cancer: A Patient/Advocate Perspective Jane Perlmutter October 8, 2015.
Uses of the NIH Collaboratory Distributed Research Network Jeffrey Brown, PhD for the DRN Team Harvard Pilgrim Health Care Institute and Harvard Medical.
Comparative Effectiveness Research (CER) and Patient- Centered Outcomes Research (PCOR) Presentation Developed for the Academy of Managed Care Pharmacy.
Patient Engagement throughout the Biopharmaceutical Lifecycle: Tips for Effective Patient Advocate/Industry Collaboration to Improve Patient Access and.
CIS 170 MART Teaching Effectively/cis170mart.com FOR MORE CLASSES VISIT HCA 497 MART Inspiring Minds/hca497mart.com FOR MORE CLASSES.
Health Management Information Systems Unit 3 Electronic Health Records Component 6/Unit31 Health IT Workforce Curriculum Version 1.0/Fall 2010.
The opportunities and challenges of sharing genomics data with the pharmaceutical industry Shahid Hanif, Head of Health Data & Outcomes, ABPI DNA digest.
PRAGMATIC Study Designs: Elderly Cancer Trials
Involving Patients in the Research Process Beverly Canin Breast Cancer Options, Inc Breast Cancer Action Cancer and Aging Research Group U13 Meeting 2015.
HCA 497 MART Experience Tradition /hca497mart.com FOR MORE CLASSES VISIT
HCA 497 NERD Real Success HCA 497 Entire Course (Ash) FOR MORE CLASSES VISIT HCA 497 Week 1 DQ 1 U.S. Health Care System vs. Other.
Logic Models How to Integrate Data Collection into your Everyday Work.
BC SUPPORT Unit: Overview and update
A capacity building programme for patient representatives
Impact and the Physical Sciences
Health Technology Assessment
DATA COLLECTION METHODS IN NURSING RESEARCH
One Approach to Bundled Payments
Patricia M. Alt, Ph.D. Dept. of Health Science Towson University
Presentation Developed for the Academy of Managed Care Pharmacy
Patient Involvement in the HTA Decision Making Process
Enrolling in Clinical Trials
Community Participation in Research
MUHC Innovation Model.
Research Translation: Lessons from Dissemination and Implementation Research for Interventions Promoting Walking and Walkability August 18, am Pacific,
Improving PCOR Methods: Causal Inference
Programme Board 6th Meeting May 2017 Craig Larlee
HEALTH IN POLICIES TRAINING
Descriptive Analysis of Performance-Based Financing Education Project in Burundi Victoria Ryan World Bank Group May 16, 2017.
Hematopoietic Cell Transplantation: Moving Beyond Survival to the Patient’s Perspective Linda J Burns, MD Medical Director, NMDP/Be The Match Health.
eHealth in the Region of the Americas:
Hans Scheurer President Myeloma Patients Europe.
Chapter 6 The Specialty of Gerontological Nursing
Support for the AASHTO Committee on Planning (COP) and its Subcommittees in Responding to the AASHTO Strategic Plan Prepared for NCHRP 8-36, TASK 138.
Presentation Developed for the Academy of Managed Care Pharmacy
Administration/Finance
Improving Your Advocacy Skills to Impact Big Data
Data Access and Stewardship
Jason Gerson, PhD Clinical Effectiveness and Decision Science
PCORI Research Priorities and Relevant Examples
SwafS Ethics and Research Integrity
Building Knowledge about ESD Indicators
Envisioning Consumer Participation
Regulated Health Professions Network Evaluation Framework
National Cancer Center
Thank you to the Congressional Public Health Caucus, which has brought us today to talk about an important issue that affects patient care and treatment,
SwafS Ethics and Research Integrity
Session 3: Coverage and Reimbursement for Genetic Testing
The Role of Data and Analytics in the Healthcare Ecosystem
Regulatory Perspective of the Use of EHRs in RCTs
THE ENVIRONMENT THAT INFLUENCES NURSING CARE
By: Andi Indahwaty Sidin A Critical Review of The Role of Clinical Governance in Health Care and its Potential Application in Indonesia.
Patient-Centered Outcomes Research Institute (PCORI)
Presentation Developed for the Academy of Managed Care Pharmacy
REACHnet: Research Action for Health Network
Presentation transcript:

Advocates & Other Big Data Stakeholders Module 4 This training was partially funded through a Patient-Centered Outcomes Research Institute (PCORI) Eugene Washington PCORI Engagement Award (1492-RUF).

The following information has been developed with assistance and input from Jane Perlmutter, PhD – Founder of Gemini Group Consulting, patient advocate, and member of the BD4P Steering Committee. This information does not constitute an endorsement by Gemini Group. Disclosure

Module Objectives Review and refine the definition of “big data” Identify stakeholders in healthcare big data Introduce some key big data issues for patients and their advocates Discuss how patients and advocates are involved in big data Compare and contrast modes of stakeholder involvement in same big data projects Module Objectives

What is Big Data?

What are the 4 Vs of Big Data? Velocity – the speed of the data. Volume – the size of the data set. Variety – the different types of data being used. Veracity – the measure of how well the data reflects reality. What are the 4 Vs of Big Data?

Modes of Data Collection Data can be collected everywhere… During the regular course of care – EHRs, medical records, doctors’ notes, diagnostic tests, etc. After regular course of care – insurance claims, treatment summaries, etc. From patient-reported data – wearables/fitness tracker information, patient-reported registries, patient-reported outcomes, health surveys, etc. From research – clinical trials, observational studies, molecular data, etc. Modes of Data Collection

Ethical Concerns of Data Collection There are ethical concerns about non-profit vs. for- profit research collection: Who has my data? Who are they sharing it with? Am I okay with a company making a profit from my data? Is/where is my data being stored? Who can access my data? Are there any other ethical concerns you can think of regarding non-profit vs. for-profit collection? Ethical Concerns of Data Collection

Types of Data/Examples Quantity/ Quality of Data Inference Method Interventional – Randomized Clinical Trials Small/ Generally Excellent Analysis of Variance Observational – Registries, Surveys, Passive Mobile Data Medium/ Very Variable Regression Unstructured – Social media, research articles Large/ Often challenging to analyze Artificial Intelligence, Natural Language Processing Big Data – Combining Multiple Types and/or Data Sources Often difficult to combine Multi-dimensional Analytics and Visualization tools What IS Big Data? This chart is one view of how big data relates to other types of data, each of which have advantages and disadvantages, and have unique approaches to drawing inferences

Types of Big Data Research Hybrids Real World Evidence Rigor Clinical Trials Molecular Databases Observational Studies Types of Big Data Hybrids Pragmatic Trials Registries Rigor Generalizability Real World Evidence Electronic Media Records (EMR) Billing Data Patient Blogs, Discussion Groups, Etc.

Data is not information, information is not knowledge, knowledge is not understanding, understanding is not wisdom. - Clifford Stoll Seek Wisdom

Why Big Data Now? One theory… Greater demand for data Across all sectors, including healthcare Increased supply of data EMRs and clinical data Advances in technology Greater functionality and ability to synthesize and analyze data More government support and utilization Focus on increasing data availability and interoperability Source: McKinsey & Company, “The Big Data Revolution in Healthcare” Why Big Data Now?

What and Who are Big Data Stakeholders? A stakeholder is an individual, business, or organization that has an interest in an particular issue, or one who is involved in or affected by a course of action Every stakeholder is going to have different interests in being involved in big data, and different roles in the data process What and Who are Big Data Stakeholders? Big Data Patients & Caregivers Advocates & Advocacy Organizations Payers Providers & Health Systems Professional Organizations Government Researchers Pharmaceutical Companies

Stakeholder Goals in Big Data Diverse stakeholders in biomedicine and health research have different needs and objectives for collecting and utilizing big data: Patients, Caregivers, and their Advocates – using the results to learn more about their conditions and benefitting from better treatments. Payers – determining which treatments are cost- effective Providers & Health Systems – informing better treatments and working in partnership with patients in patient-centered and evidence-based care Researchers (including governments and pharmaceutical companies) – analyzing results to make advancements in treatments and therapies Stakeholder Goals in Big Data

Outcomes of Big Data Use How do innovations and the use of big data affect diverse stakeholders? Patients & Caregivers More effective and efficient treatments Opportunities to participate in initiatives Better understanding of disease and treatment options Advocates & Advocacy Organizations Better understanding of disease and how to advocate Promotion of patient-centered treatments and therapies Payers Finding new methods to increase value and quality while decreasing costs Changing payment structures based on insights from big data Outcomes of Big Data Use

Outcomes of Big Data Use (cont.) Providers & Health Systems Increase in use of evidence-based medicine and personalized treatments Researchers (including governments and pharmaceutical organizations) A move towards new forms of research and gain more comprehensive information Using new tools and innovations to change policies and standards Obtaining better, more effective, and cost-efficient therapies Outcomes of Big Data Use (cont.)

Concerns Common to All Big Data Stakeholders Interoperability and data standardization – will the data be useable? Exchange of data – will the data be able to be read by those who need to read it? Access of information – will the data be accessible to those who need to obtain it? Ensuring security and privacy – will the data be securely obtained, held, and disseminated? Concerns Common to All Big Data Stakeholders

Sponsors and investigators share many of the same concerns that patients/advocates do, though they sometimes take a backseat to technical and scientific concerns. Patient advocates are more focused on patient issues. Patient advocates have a responsibility to bring the patient issues to the forefront. Patients can help to identify incorrect information that could lead to inaccurate data sets (i.e. wrong procedure/billing codes) Advocacy Reminders

Big Data Issues Especially Important to Patients/ Advocates For research projects & big data initiatives: How representative are the data of the population? Who pays for the data and infrastructure and how is it sustained? Who profits from the project? Does the informed consent meet best ethical and patient-friendly practices? What plans are in place to return results to those who contribute data? What are the research priorities? Big Data Issues Especially Important to Patients/ Advocates

For research projects & big data initiatives: What data controls have been established? How are the data cleaned and/or curated? Is there a data monitoring plan? How will missing data be handled? Are there other checks and balances? What data sharing plans have been established? Are common data elements and other standards used, when feasible? Are the data readily available to all comers? Are guidelines in place to vet requests for data? Is there adequate funding and other support to facilitate sharing? Big Data Issues Especially Important to Patients/ Advocates – QUESTIONS TO ASK

For research projects & big data initiatives: What security and privacy measures have been established? Do the security and privacy practices meet minimal legal and regulatory requirements? What are the trade-offs for establishing more or less stringent requirements? What’s behind the models, algorithms, and parameters? What assumptions are built into the model? What is the evidence to support them? Have you done a sensitivity analysis of the sensitivity to the assumptions, algorithms, and parameters in the model? What is your evaluation and improvement plan? Big Data Issues Especially Important to Patients/ Advocates – QUESTIONS TO ASK (cont.)

From Patient to Research Advocate Patients Advocates Research Advocates From Patient to Research Advocate Have somewhat longer term perspective Want to prevent others from going through what they have Have a great diversity of knowledge, opinions, and approaches On average, more interested and knowledgeable about science Want to ensure that research is efficient, effective, and patient-focused Cannot wait Often cannot advocate for themselves Often willing to take great risk for low probability of gain

Different Roles for Different Folks Type of Advocate Most Effectively Involved Survivor with a Personal Compelling Story Clarify (naïve) concerns among diverse patients Generate media attention Impact legislators and regulators Staff Member of Advocacy Organization Identify potential contributors of data to big data projects Identify potential advocates to inform big data projects Clarify and advocate about big data policy issues Inform and activate community about big data research efforts and policy Individual Research Advocate Provide (informed) input on patient needs, concerns, and priorities Influence big data research efforts and policy issues Review informed consent documents and big data contributor educational material Different Roles for Different Folks

How are Patients and the Public Involved in Big Data? Contribute their data, knowingly and unknowingly Fundraise, directly and indirectly Lobby for health research Prioritize questions and research efforts that are important to patients Be active members of big data steering committees and advisory boards Review informed consent documents and other educational materials Help inform the public about big data Provide patient perspective on big data panels How are Patients and the Public Involved in Big Data?

Summary: Advocate View of Big Data The promise is huge… ...But there are risks Promise Risk Better predictions about health risks Immature methodology  erroneous inferences Faster development of treatments Breach of security  loss of privacy More rapid progress toward precision medicine Hoarding of data  slowing progress More efficient use of health resources Summary: Advocate View of Big Data

How to Make a Difference? Ensure patients/advocates are “at the table” and heard when decisions are made about big data projects Inform patients/advocates and the public about potential benefits and concerns associated with health data (messaging, training) Be discriminating in providing support to excellent projects and encouraging patients and researchers to share data Learn more How to Make a Difference?

Big data has lots of potential, but it’s more complicated than we can imagine Technical issues Political/economic issues Patient ethical issues Including patients/advocates from the beginning will lead to better, faster, and more acceptable results Take Home Messages

Modes of Stakeholder Involvement in Sample Big Data Projects Goals Modes of data collection Potential outcomes Funding Stakeholder involvement Modes of Stakeholder Involvement in Sample Big Data Projects

What are Similarities & Differences Among these Initiatives? Cancer Big Data Examples ‘Omics – Visualization, analysis and download of large-scale cancer genomics data sets for research Example: NCI’s The Cancer Genome Atlas, cBioPortal for Cancer Genomics Learning Systems – Real-world data for quality improvement and research Example: ASCO’s CancerLinQ, Flatiron Health, The Athena Breast Health Network Clinical Trials – Data sharing from clinical trials for research Example: Project Data Sphere What are Similarities & Differences Among these Initiatives?

What are Similarities & Differences Among these Initiatives? Other Health Examples Surveillance – multi-source data to monitor unidentified toxicities and drug interactions Example: FDA’s Sentinel Initiative Patient-Entered Data – patient support and information sharing Example: PatientsLikeMe Artificial Intelligence Processing – analyzing data and providing patient support Example: IBM Watson Health What are Similarities & Differences Among these Initiatives?